Spero Therapeutics Inc (SPRO) Stock Price, Quote & News

Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 242 1600

Website: sperotherapeutics.com

Address:

675 Massachusetts Avenue, 14th Floor, Cambridge, United States

MikeyMcDermott Jul. 4 at 1:26 AM

$SPRO $GSK $NUVL wilmer hale, leerink, mintz, pwc, ropes & gray ... someone in Boston knows something imo CLOSE BIZ -- then go watch the Boston Pops at the Hatch Shell Ampitheatre on the Charles River Esplanade .... if it isn't too hot

0 · Reply

MikeyMcDermott Jul. 4 at 1:23 AM

$SPRO Mintz Levin is SPRO corporate law firm for a long time -- not sure if Mintz totally lost Spero now that Wilmer Hale is doing stuff. But Mintz wading into reverse merger PIPE deals like with RallyBio and Longwood Fund portfolio company Avenzo Therapeutics Mintz is a serious white shoe law firm particularly in IP / life sciences in Boston market. (wilmer hale serious too)

0 · Reply

MikeyMcDermott Jul. 4 at 1:18 AM

$SPRO Leerink advised $GSK in the $NUVL deal https://investors.nuvalent.com/2026-06-09-GSK-enters-agreement-to-acquire-Nuvalent,-Inc

0 · Reply

MikeyMcDermott Jul. 4 at 1:15 AM

$SPRO or Leerink Partners?

0 · Reply

MikeyMcDermott Jul. 4 at 12:53 AM

$SPRO $GSK growth pivot probably requires about 400-500 million net cash on balance sheet for 3rd party reverse merger target to accept ... 350-500 million seems like sweet spot for Candid Therapeutics, Korsana Bio, Obsidian, Avenzo deals since March.

0 · Reply

MikeyMcDermott Jul. 4 at 12:48 AM

doubtful. Put another way, $SPRO retains about 8-10% of tebi rights. Let's call to 10% for round numbers. What you are saying is Tebi is worth $10 billion today. ~600 million UPFFONT gets it done imo Let's go $GSK

1 · Reply

MikeyMcDermott Jul. 4 at 12:23 AM

Paul Hastings, eh? $SPRO $LGND ? $XOMA ? $KLRA $GSK ?

0 · Reply

IDDoc Jul. 3 at 10:57 PM

$SPRO No potential competition active on clinicaltrials.gov means moat for years If history guides, number of use cases could double over the next 10 years. ROW also huge SPRO mgmt may be holding out for much more than $1 Billion upfront.

0 · Reply

MikeyMcDermott Jul. 3 at 6:50 PM

$SPRO I suppose if laying off ~10 staff, it would be good to do after the holiday break alongside transaction details. Probably salary out to Sept 15 and then some form of cash severance/accelerated equity vesting.

1 · Reply

BxxZ Jul. 3 at 2:56 PM

$SPRO $GSK SM is closed but nonetheless Esther is fighting hard & negotiating the final outcome..... She & the Spro Board are genuine hard workers & hard work is always 10fold repaid (min!)..... So - do the extra mile and end Story nr.1, for the SH to fully embrace the bright path into New Growth Era!!! 🤣🤣🤣

0 · Reply

Spero Therapeutics Transcript: AGM 2026

Jun 17, 2026, 4:21 PM EDT - 16 days ago

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK

2026-06-17T15:17:18.000Z - 17 days ago

GSK, Spero Therapeutics announce FDA approval of Utebzi

GSK

May 13, 2026, 4:05 PM EDT - 7 weeks ago

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

May 13, 2026, 4:00 PM EDT - 7 weeks ago

Spero Therapeutics Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 7 weeks ago

Spero Therapeutics Quarterly report: Q1 2026

May 5, 2026, 4:05 PM EDT - 2 months ago

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Spero Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Spero Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Spero Therapeutics Proxy statement: Proxy filing

Mar 26, 2026, 4:05 PM EDT - 3 months ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Mar 26, 2026, 4:00 PM EDT - 3 months ago

Spero Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 3 months ago

Spero Therapeutics Annual report: Q4 2025

Mar 18, 2026, 4:05 PM EDT - 3 months ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

2025-12-19T13:17:06.000Z - 7 months ago

Spero announces GSK filed NDA resubmission to FDA for tebipenem HBr

GSK

Dec 19, 2025, 8:00 AM EST - 7 months ago

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

2025-11-28T13:10:22.000Z - 7 months ago

Spero Therapeutics announces inducement grant under Nasdaq listing rule

Nov 28, 2025, 8:00 AM EST - 7 months ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2025, 4:05 PM EST - 8 months ago

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Nov 13, 2025, 4:00 PM EST - 8 months ago

Spero Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

Spero Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 4:05 PM EST - 8 months ago

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

2025-10-21T09:50:26.000Z - 9 months ago

Spero Therapeutics, GSK announce PIVOT-PO trial efficacy and safety results

GSK

Oct 21, 2025, 2:00 AM EDT - 9 months ago

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Spero Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Spero Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Spero Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:01 PM EDT - 11 months ago

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

Aug 5, 2025, 4:05 PM EDT - 11 months ago

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Spero Therapeutics Slides: Corporate Presentation

2025-05-28T20:13:00.000Z - 1 year ago

Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data

GSK

2025-05-28T11:20:29.000Z - 1 year ago

GSK reports PIVOT-PO study for tebipenem HBr stopped early for efficacy

GSK

2025-05-28T11:11:24.000Z - 1 year ago

Spero Therapeutics, GSK announce Phase 3 PIVOT-PO trial met primary endpoint

GSK

May 28, 2025, 7:00 AM EDT - 1 year ago

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GSK

May 13, 2025, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 13, 2025, 4:00 PM EDT - 1 year ago

Spero Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Spero Therapeutics Quarterly report: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

2025-04-28T20:11:11.000Z - 1 year ago

Spero Therapeutics appoints Esther Rajavelu will serve as CEO

Apr 28, 2025, 4:01 PM EDT - 1 year ago

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Spero Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Spero Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Spero Therapeutics Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Spero Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Spero Therapeutics Earnings release: Q4 2024

2025-03-27T20:20:55.000Z - 1 year ago

Spero Therapeutics reports Q4 EPS (38c), consensus (31c)

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Mar 4, 2025, 3:10 PM EST - 1 year ago

Spero Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 10:15 AM EST - 1 year ago

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

2025-01-10T12:31:40.000Z - 1 year ago

Spero Therapeutics announces interim leadership changes

Jan 10, 2025, 7:00 AM EST - 1 year ago

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

2024-12-20T11:16:22.000Z - 1 year ago

Spero Therapeutics downgraded at Evercore on lack of capital allocation clarity

2024-12-20T10:45:23.000Z - 1 year ago

Spero Therapeutics downgraded to In Line from Outperform at Evercore ISI

2024-11-18T12:41:28.000Z - 1 year ago

Spero Therapeutics downgraded to Hold from Buy at TD Cowen

2024-11-14T21:20:42.000Z - 1 year ago

Spero Therapeutics reports Q3 EPS (32c), consensus (36c)

Nov 14, 2024, 4:05 PM EST - 1 year ago

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Nov 14, 2024, 12:00 AM EST - 1 year ago

Spero Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 12:00 AM EST - 1 year ago

Spero Therapeutics Quarterly report: Q3 2024

2024-11-04T11:10:15.000Z - 1 year ago

Spero Therapeutics price target lowered to $5 from $7 at H.C. Wainwright

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Oct 2, 2024, 4:30 PM EDT - 1 year ago

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Sep 17, 2024, 1:20 PM EDT - 1 year ago

Spero Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:00 PM EDT - 1 year ago

Spero Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 5, 2024, 4:30 PM EDT - 2 years ago

Spero Therapeutics Earnings Call Transcript: Q2 2024

Aug 5, 2024, 4:30 PM EDT - 2 years ago

Spero Therapeutics Quarterly report: Q2 2024

Aug 5, 2024, 4:30 PM EDT - 2 years ago

Spero Therapeutics Earnings release: Q2 2024

Aug 5, 2024, 4:01 PM EDT - 2 years ago

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Jul 29, 2024, 4:05 PM EDT - 2 years ago

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

May 20, 2024, 1:30 PM EDT - 2 years ago

Spero Therapeutics Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 16, 2024, 4:05 PM EDT - 2 years ago

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

May 15, 2024, 4:05 PM EDT - 2 years ago

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 15, 2024, 4:00 PM EDT - 2 years ago

Spero Therapeutics Quarterly report: Q1 2024

May 15, 2024, 4:00 PM EDT - 2 years ago

Spero Therapeutics Earnings release: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

May 1, 2024, 4:07 PM EDT - 2 years ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Spero Therapeutics Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Spero Therapeutics Proxy statement: Proxy Filing

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Spero Therapeutics Registration statement: Registration Filing

Mar 13, 2024, 4:30 PM EDT - 2 years ago

Spero Therapeutics Earnings Call Transcript: Q4 2023

Mar 13, 2024, 4:30 PM EDT - 2 years ago

Spero Therapeutics Annual report: Q4 2023

Mar 13, 2024, 4:30 PM EDT - 2 years ago

Spero Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Mar 6, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Mar 4, 2024, 9:50 AM EST - 2 years ago

Spero Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Feb 26, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Jan 5, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Jan 2, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Nov 28, 2023, 7:55 AM EST - 2 years ago

Spero Therapeutics Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 4:30 PM EST - 2 years ago

Spero Therapeutics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

Spero Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

Spero Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 1, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Nov 1, 2023, 7:45 AM EDT - 2 years ago

Spero Therapeutics Slides: Investor Presentation

Sep 20, 2023, 4:05 PM EDT - 3 years ago

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Sep 6, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 1, 2023, 8:00 AM EDT - 3 years ago

Spero Therapeutics Proxy statement: Proxy Filing

Aug 22, 2023, 8:00 AM EDT - 3 years ago

Spero Therapeutics Proxy statement: Proxy Filing

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Spero Therapeutics Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Spero Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Spero Therapeutics Earnings release: Q2 2023

Aug 3, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 31, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Jun 14, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

May 11, 2023, 4:30 PM EDT - 3 years ago

Spero Therapeutics Earnings Call Transcript: Q1 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

Spero Therapeutics Quarterly report: Q1 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

Spero Therapeutics Earnings release: Q1 2023

May 11, 2023, 4:05 PM EDT - 3 years ago

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

May 4, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Apr 26, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Present at Upcoming Investor Conference

Apr 14, 2023, 8:05 AM EDT - 3 years ago

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

MikeyMcDermott Jul. 4 at 1:26 AM

0 · Reply

MikeyMcDermott Jul. 4 at 1:23 AM

0 · Reply

MikeyMcDermott Jul. 4 at 1:18 AM

$SPRO Leerink advised $GSK in the $NUVL deal https://investors.nuvalent.com/2026-06-09-GSK-enters-agreement-to-acquire-Nuvalent,-Inc

0 · Reply

MikeyMcDermott Jul. 4 at 1:15 AM

$SPRO or Leerink Partners?

0 · Reply

MikeyMcDermott Jul. 4 at 12:53 AM

0 · Reply

MikeyMcDermott Jul. 4 at 12:48 AM

1 · Reply

MikeyMcDermott Jul. 4 at 12:23 AM

Paul Hastings, eh? $SPRO $LGND ? $XOMA ? $KLRA $GSK ?

0 · Reply

IDDoc Jul. 3 at 10:57 PM

0 · Reply

MikeyMcDermott Jul. 3 at 6:50 PM

1 · Reply

BxxZ Jul. 3 at 2:56 PM

0 · Reply

MikeyMcDermott Jul. 2 at 9:27 PM

Apparently an FDA approval for a biotech shitco that owns 10% of a drug gets same reaction as a biotech shitco that owns 100% of its drug which gets a CRL. $SPRO vs $UNCY 3+ days after FDA

0 · Reply

BxxZ Jul. 2 at 8:46 PM

$SPRO $GSK How low can U go? (not Spro - actually GSK!!!) Fuj in fej - MUPM

0 · Reply

MikeyMcDermott Jul. 2 at 7:04 PM

No. The scientists in The People's Republic of Cambridge are killing this stock by not unlocking value. $SPRO

0 · Reply

GeneralGainz Jul. 2 at 6:40 PM

$SPRO This is WAY too low after getting FDA approval. Going to load another 10k shares from my $NFLX profits after earnings into this!

1 · Reply

Inc82 Jul. 2 at 5:59 PM

$SPRO The shorts are killing this stock.

0 · Reply

Inc82 Jul. 2 at 5:57 PM

$SPRO what a disaster!

0 · Reply

DDel Jul. 2 at 5:24 PM

$SPRO bought more, again. gsk for the win.

0 · Reply

Zalsalman Jul. 2 at 3:37 PM

Hello $SPRO Is anyone from the company here? 👀 Why is everything so quiet?

1 · Reply

BxxZ Jul. 2 at 1:59 PM

$SPRO $GSK The stock market does not predict any tebi rights buy or RM being on the horizon!!! What they do predict is stubburn intention of the mgt. to go alone on their New Growth phase project - meaning new shares to be issued (up to 120m for measly 240-250m????) and dillution of current shareholders into oblivion (less than 1/3 rd of ownership) - all just for mgt's wish for their new journey!!! Well Esther - there is another path ; prepare Cost saving plan & make everybody apart from yourself (actually being only a shell also you could work part-time!!!) redundant. All U need is external accountancy&legal support!!! To much to ask being dependant only on GSK checks?! Doubt so!!! Makes far more sense than your alone fantasy growth story (current leadership is not up to it!!!)...... So, in case WS is correct do not dream of "yoir own story" and if there eis no discusion with GSK just do your job and reduce costs!!!!

3 · Reply

BxxZ Jul. 2 at 11:58 AM

$SPRO $GSK Seems Forrest is tired.... Better let him rest through summer to be fully "reffiled" in Sept/Oct. Lost opp's & tight dates do not matter. Procrastination is becoming his new "motto". 🤣🤣🤣

0 · Reply

MikeyMcDermott Jul. 1 at 11:54 PM

Hope $SPRO doesnt sell for 40 cents on the dollar like the Celts did with Jaylen Brown

1 · Reply

MikeyMcDermott Jul. 1 at 9:50 PM

fwiw, the $CYCN and Korsana Biosciences reverse merger deal was executed on April 1, 2026. Is there something special about first day of new quarter or these reverse merger deals? Either something about SEC reporting / clean break for a new quarter or confirmation bias cc $SPRO $GSK

0 · Reply

Market Cap	127.38M
Revenue (ttm)	66.80M
Net Income (ttm)	8.57M
EPS (ttm)	N/A
PE Ratio	9.25
Forward PE	N/A
Profit Margin	12.83%
Debt to Equity Ratio	0.00

Volume	629,500
Avg Vol	1,113,554
Day's Range	N/A - N/A
Shares Out	57.90M
Stochastic %K	54%
Beta	1.49
Analysts	Sell
Price Target	$4.50